Venetoclax Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma

  • End date
    Jun 1, 2022
  • participants needed
  • sponsor
    Nordic Lymphoma Group
Updated on 26 January 2021


Phase I/II trial, with the aim of evaluating the efficacy of venetoclax to the backbone of rituximab-lenalidomide in patients with relapsed/refractory MCL.

Condition Relapsed Non Hodgkin Lymphoma
Treatment venetoclax
Clinical Study IdentifierNCT03505944
SponsorNordic Lymphoma Group
Last Modified on26 January 2021


Yes No Not Sure

Inclusion Criteria

Age >18 years
Histologically confirmed (according to the WHO 2016 classification) mantle cell lymphoma stage I-IV
Who have received at least 1 prior rituximab-containing chemotherapy regimen, with documented relapse or disease progression following the last anti-MCL treatment OR
Are not considered to be candidates for chemotherapy due to frailty or comorbidity
At least 1 measurable site of disease (>1.5 cm long axis)
WHO performance status 0 - 3
Written informed consent
Female subjects of childbearing potential must (see page 52 for definition of not fertile)
Understand that the study medication is expected to be teratogenic
Agree to use, and be able to comply with, highly effective contraception without interruption, 4 weeks before starting study drug, throughout study drug therapy (including dose interruptions) and for 4 weeks after the end of study drug therapy, even if she has amenorrhoea
All fertile women must agree to perform monthly pregnancy tests while on study medication and until 4 weeks after completion of study drug. Tests must have a minimum sensitivity of 25 mIE/ml and be medically witnessed
Highly effective contraception include
Implant _Levonorgestrel-releasing intrauterine system (IUS)_
Medroxyprogesterone acetate depot Tubal sterilisation Sexual intercourse with
a vasectomised male partner only; vasectomy must be confirmed by two negative
semen analyses Ovulation inhibitory progesterone-only pills (i.e
desogestrel) NB! Patients using a hormonal method, must also use a second
barrier method. Sexual abstinence (if refraining from heterosexual intercourse
during the entire period of risk associated with the study treatments. The
reliability of sexual abstinence needs to be evaluated in relation to the
preferred and usual lifestyle of the subject)
Male subjects must
Agree to use condoms throughout study drug therapy, during any dose interruption and for one week after cessation of study therapy if their partner is of childbearing potential and has no contraception
Agree not to donate semen during study drug therapy and for one week after end of study drug therapy
All subjects must
Agree to abstain from donating blood while taking study drug therapy and for one week following discontinuation of study drug therapy
Agree not to share study medication with another person and to return all unused study drug to the investigator

Exclusion Criteria

Chemotherapy or radiotherapy within 3 weeks
Therapeutic antibodies or BTK inhibitors within 4 weeks
Radioimmunotherapy within 10 weeks
Major surgery within 4 weeks of inclusion in this trial
Previous treatment with venetoclax
Impaired liver function: AST and ALT >3.0 the upper normal limit (ULN) of institution's normal range; Bilirubin > 1.5 ULN. Subjects with Gilbert's Syndrome may have a bilirubin > 1.5 ULN, per discussion between the investigator and medical monitor. Elevated Bilirubin due to haemolytic anemia or caused by lymphoma, is not an exclusion criterion
Absolute neutrophil count (ANC) <1.0x 109, unless caused by bone marrow infiltration by lymphoma
Platelet count <60 x 109, unless caused by bone marrow infiltration by lymphoma
Creatinine clearance below 50 ml/min (Cockcroft-Gault)
Known CNS lymphoma
Heart failure in NYHA stage IV or other serious CVD
Pulmonary failure (ex chronic disease with hypoxemia)
Active serious infections such as hepatitis B or C and HIV
Conditions with serious immunocompromised state
Breastfeeding women must be excluded or stop breastfeeding
Other active malignancy
Psychiatric illness or condition which could interfere with the subjects' ability to understand the requirements of the study
Requirement of corticosteroid therapy at a dose >10 mg prednisolone/day
Hypersensitivity to venetoclax, lenalidomide or rituximab, or HACA against rituximab
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note